CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 506 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
0.15% azelastine hydrochloride 822 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00824473
NCT00824473Phase 3Completed
CompareCT.gov

Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Subjects With Seasonal Allergic Rhinitis

Meda Pharmaceuticals·interventional·Posted Jan 16, 2009·Updated Feb 23, 2010

In Brief

A Phase 3 clinical trial evaluating Placebo and 0.15% azelastine hydrochloride for Seasonal Allergic Rhinitis. Completed, enrolled 506 participants across 7 sites.

Detailed Summary

The purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 16, 2009
Enrollment StartDec 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.5 years ago

Interventions

Placebodrug

Placebo

0.15% azelastine hydrochloridedrug

0.15% azelastine hydrochloride 822 mcg